Weight loss is the new religion, and pharma companies are its priests. While half of Instagram is injecting reels into veins, Eris is prepping to inject Semaglutide into actual patients. Novo’s insulin exit has left a ₹600–800 crore-sized hole in the market, and Eris is already sharpening its needles. Meanwhile, management kept reminding us: “trust the process” — which usually means “don’t look at this quarter, look at the next one.”
Read on — because between insulin shortages, GLP-1 gossip, and a trade generics funeral, this is spicier than your doctor’s prescription pad.
2. At a Glance
Revenue ₹773 Cr (+7.4%) – Growth slower than a Mumbai local at rush hour.
DBF Revenue ₹702 Cr (+11%) – Outrunning IPM by 330 bps; bragging rights intact.
EBITDA Margin 36% (↑100 bps) – Margins are flexing like gym bros in January.
Trade Generics Revenue ₹3 Cr (vs ₹13 Cr) – Someone please call a priest; segment is dead.
3. Management’s Key Commentary
Quote: “DBF business grew 11% this quarter, outperforming IPM by 330 bps.” (Translation: We’re still faster than the industry treadmill, but sweating a lot more.)
Quote: “Operating margin of Biocon segment expanded from 19% to 30%.” (Translation: This acquisition finally stopped being a freeloading cousin at Diwali.)
Quote: “We’ve commenced insulin vial manufacturing at Bhopal.” (Translation: Vials are here, cartridges are still playing hard-to-get.)
Quote: “GLP-1 market formation in India is happening post LoE, and demand is very encouraging.” (Translation: Every second gym bro now thinks injections are faster than squats.)
Quote: “Export revenue fell to ₹68 Cr vs ₹74 Cr; Swiss business is lumpy.” (Translation: Shipments come like Indian trains — not on time, but eventually.)
Quote: “We’ve decided to ramp down the Trade Generics business.” (Translation: This side hustle wasn’t hustling, just wasting petrol.)
Quote: “Net debt at ₹2,300 Cr; target ₹1,800 Cr by year-end.” (Translation: Debt diet plan active, but insulin stockpile cheated meal.)
